Sichuan Biokin Pharmaceutical Co: Q3 earnings rebounded, while 9M losses and R&D-driven cash outflow remained substantial
Less than 1 min read
Q3 revenue and net income increased, but 9M results remained loss-making as R&D spending exceeded revenue and operating cash outflow reached RMB 2.168bn. The IZABRIGHT-Lung02 milestone triggered a second $250m contingent-payment condition.
Original document: [Sichuan Biokin Pharmaceutical Co., Ltd. Class A [688506] Interim report — Oct. 30 2026](https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Areport%3Aquartr.com%3A4089712-180d3326bdeff6ce55cbe2bb36bd5709)
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr